The present mini-review therefore aims to summarize the contribution of ED to CVD in obesity and T2DM, to synthesize the pre-clinical and clinical evidence supporting endothelial and cardiovascular benefits of GLP-1RAs, and to delineate current controversies and research priorities that will inform future incretin-modulating interventions. This evidence concerns the gene GCG and type 2 diabetes mellitus.